CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
CCTG is pleased to announce the agenda for the Plenary Session at the #CCTG2026 Spring Meeting.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
SC26 Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia has been centrally activated.
MAC7 (NCT00075764) trial: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer has been permenantly closed.
Objectives: To compare time to tumour progression in post-menopausal women with metastatic breast cancer treated with anastrozole versus anastrozole and fluvestrant. For more information please visit the CCTG MAC7 trial page.
REC.3 (NCT02761057), A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005],Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET), has been closed to accrual after completion of target accrual. Treatment and follow-up of accrued patients will continue according to the protocol.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.
The CCTG Central Office will be closed on some dates during the holidays with partial staff coverage, there is also information on shipment of specimens for banking and kit supply and BARL holiday schedule. Web-based applications (i.e. MANGO, GCP) will still be available and regular business hours will resume on Thursday, January 2, 2020 at 8:30 am EST.
Next year is almost here and in 2020 CCTG will be marking our 40th anniversary! We would like to recognize this milestone and the hard work of our clinical trials network across Canada at an anniversary celebration during the 2020 CCTG Spring Meeting.
Event details to follow in the New Year - make sure to save the date and celebrate 40 years of clinical trial excellence.
